Arbutus Biopharma Corp. (NASDAQ:ABUS) shares dropped 3.7% during trading on Wednesday . The company traded as low as $3.59 and last traded at $3.61, with a volume of 107,842 shares changing hands. The stock had previously closed at $3.75.

ABUS has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Monday, April 25th. Leerink Swann reiterated a “buy” rating on shares of Arbutus Biopharma Corp. in a research note on Wednesday, July 20th. Chardan Capital lowered shares of Arbutus Biopharma Corp. from a “neutral” rating to a “sell” rating and decreased their price target for the company from $3.25 to $2.75 in a research note on Friday, July 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Arbutus Biopharma Corp. in a research note on Wednesday, May 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $9.79.

The stock has a 50-day moving average price of $3.98 and a 200 day moving average price of $3.96. The firm’s market cap is $197.81 million.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.36. Equities research analysts expect that Arbutus Biopharma Corp. will post ($3.28) earnings per share for the current year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.